Clinical trials: Escitalopram
Depression, Inflammation
Stress and Inflammation in Late-Life Depression
Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that there is a link between depression and inflammatory disease.
- Trial name
- S&I (NCT02389465)
- Testing
- Escitalopram + Celecoxib
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Depression
Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression
PRECISE-D is a single site, randomized, open label 8-week clinical trial that will enroll 70 participants to evaluate if the level of inflammation in our body can predict how we will respond to antidepressants.
- Trial name
- PRECISE-D (NCT03993457)
- Testing
- Escitalopram, Bupropion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Depression
Advancing Personalized Antidepressant Treatment Using PET/MRI
Despite current medications, morbidity and mortality of Major Depressive Disorder (MDD) remain high. According to the World Health Organization, MDD affects 121 million people worldwide, and is projected to be the second leading…
- Trial name
- NCT02623205
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Stony Brook University
Anxiety Disorders,Generalized Anxiety Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD.
- Trial name
- NCT03924323
- Testing
- Escitalopram
- Where
- 39 sites in United States
- Volunteers
- 273 people
- Sponsor
- AbbVie
Major Depressive Disorder
Study of Neural Responses Induced by Antidepressant Effects
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
- Trial name
- SONRISA (NCT02674529)
- Testing
- Escitalopram, Real-time Neurofeedback fMRI task pre- and post-RCT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marta Peciña, MD PhD
Post Traumatic Stress Disorder, Major Depressive Disorder
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
In the Investigator's ongoing studies of Posttraumatic Stress Disorder (PTSD) in older adults, it has been found that older adults with PTSD frequently meet the criteria for comorbid Major Depressive Disorder (MDD).
- Trial name
- NCT04697693
- Testing
- Escitalopram, Duloxetine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Contact: Developing New Clinical Management Strategies
The goal of this study is to develop new methods of administering antidepressant medications that will result in improved drug/placebo separation in randomized controlled trials (RCTs) for Major Depressive Disorder (MDD) and…
- Trial name
- NCT03812588
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture
This will be a randomized, single blind study of 6 weeks duration involving the use of auricular acupuncture or sham acupuncture in the adjunctive treatment of depression in college students.
- Trial name
- NCT02579343
- Testing
- Auricular Acupuncture
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Florida Gulf Coast University
Hearing Loss, Depression
Treating Hearing Loss to Improve Mood and Cognition in Older Adults
Age-related hearing loss (ARHL) is the third most common health condition affecting older adults after heart disease and arthritis and is the fifth leading cause of years lived with disability worldwide.
- Trial name
- NCT03321006
- Testing
- Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Connectivity Affecting the Antidepressant REsponse Study
It can be difficult to achieve remission in individuals with late-life depression (LLD) and they often require aggressive treatment. This challenge is in part due to age-related vascular changes that are common in LLD.
- Trial name
- CAARE (NCT02332291)
- Testing
- Escitalopram, Bupropion XL
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt University Medical Center
Depression
Adherence to Antidepressant Treatment in Subjects With Depression
This study aims to determine whether a combination a first-line antidepressant plus "RT2CK17" in a capsule relative to a first-line antidepressant plus placebo in a capsule results in higher rates of medication adherence in…
- Trial name
- NCT03388164
- Testing
- Escitalopram + RT2CK17
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Anxiety, Cardiovascular Disease
Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
Coronary heart disease (CHD) is the leading cause of death in the United States; more than 600,000 Americans suffer a fatal cardiac event each year.
- Trial name
- NCT02516332
- Testing
- Lexapro, Supervised Aerobic Exercise
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Duke University
Major Depressive Disorder, Dysthymic Disorder
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
- Trial name
- NCT01973283
- Testing
- Antidepressant Medication
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Depression
The ISLAND Study: InSuLa Assessed Needs for Depression
While there are many effective options for treating a major depressive episode, there are no clinical markers that predict the likelihood of remission with an initial trial of either an antidepressant medication or psychotherapy.
- Trial name
- ISLAND (NCT02137369)
- Testing
- Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT)
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Anxiety, Depression
Anxiety and Depression in Epilepsy: A Treatment Study
As a potential solution to address high rates of depression and anxiety seen in epilepsy patients and poor mental health care access, this randomized trial aims to study treatment for anxiety and depression in epilepsy taking…
- Conditions
- Anxiety, Depression, Epilepsy
- Trial name
- NCT03464383
- Testing
- Escitalopram 10mg, Referral to Psychiatry, Survey only
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Wake Forest University Health Sciences